Providence, RI—Among nearly 10,000 nursing home residents in the United States included in a recent study, second mRNA COVID-19 vaccine booster doses provided significant additional protection over first booster doses against severe COVID-19 outcomes, even though the Omicron variants were emerging.

“In this analysis, comparing the relative effectiveness of a second booster dose of COVID-19 mRNA vaccines with a single booster dose among eligible nursing home residents in 19 states, VE [vaccine effectiveness] of a second booster dose against the severe composite outcomes of SARS-CoV-2–associated hospitalization or death was 73.9% and 89.6% for death alone,” wrote researchers from the Veterans’ Administration Medical Center and Brown University, both in Providence, RI, and colleagues. “VE against SARS-CoV-2 infection during a period crossing both Omicron subvariants BA.2 and BA.2.12.1 (March–June 2022) and BA.4 and BA.5 (July 2022) predominance was 25.8%.”

The background information in the study, published in the Morbidity & Mortality Weekly Report, pointed out that nursing home residents have continued to experience significant COVID-19 morbidity and mortality compared with other U.S. cohorts.

In March 2022, the Advisory Committee on Immunization Practices (ACIP) recommended a second mRNA COVID-19 vaccine booster dose for adults aged 50 years and older and all immunocompromised people who had received a first booster 4 or more months earlier. More recently, on September 1, 2022, the ACIP voted to recommend bivalent mRNA COVID-19 vaccine boosters for all people aged 12 years and older who had completed the primary series using monovalent vaccines 2 or more months earlier.

The authors pointed out that data on COVID-19 booster dose VE in the nursing home population are limited. In this analysis, academic, federal, and private sector researchers evaluated routine care data collected from 196 U.S. community nursing homes to estimate VE of a second mRNA COVID-19 vaccine booster dose among nursing home residents who had received three previous COVID-19 vaccine doses—two primary series doses and one booster dose.

The residents who received second mRNA COVID-19 vaccine booster doses during March 29 through June 15, 2022, with follow-up through July 25, 2022, were found to have:

• 60-day VE of 25.8% against SARS-CoV-2 (the virus that causes COVID-19 infection)
• 73.9% against severe COVID-19 outcomes (a combined endpoint of COVID-19-associated hospitalizations or deaths)
• 89.6% against COVID-19-associated deaths alone.

“During this period, subvariants BA.2 and BA.2.12.1 (March–June 2022), and BA.4 and BA.5 (July 2022) of the B.1.1.529 and BA.2 (Omicron) variant were predominant,” the authors advised. “These findings suggest that among nursing home residents, second mRNA COVID-19 vaccine booster doses provided additional protection over first booster doses against severe COVID-19 outcomes during a time of emerging Omicron variants. Facilities should continue to ensure that nursing home residents remain up to date with COVID-19 vaccination, including bivalent vaccine booster doses, to prevent severe COVID-19 outcomes.”

Nursing home residents who had been vaccinated on a specific index date were assigned to the treatment group, while those who were unvaccinated but eligible were assigned as the control group. The researchers determined vaccination status using residents’ immunization records from nursing home electronic health record systems.

Their analysis included 9,527 unique residents from 196 nursing homes. Among the residents, 9,503 (99.7%) served as controls for ≥1 day of follow-up and 3,245 (34.1%) residents received a second booster dose during the study period and were eligible to be included in the treatment group.

“These results indicate that, compared with a single mRNA COVID-19 vaccine booster dose, a second booster dose provided additional protection against COVID-19-associated severe outcomes among nursing home residents during the Omicron period ending with BA. 4 and BA. 5 dominances,” the researchers concluded. “The results support the importance of continued efforts to ensure the nursing home population is up to date on recommended COVID-19 vaccine booster doses including the newly authorized bivalent COVID-19 vaccine.”

The content contained in this article is for informational purposes only. The content is not intended to be a substitute for professional advice. Reliance on any information provided in this article is solely at your own risk.

 « Click here to return to Diabetes Update.